BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
The most effective method to Beat Dental Tension and Guarantee Customary Exams- Doggie diversity in size and shape began at least 11,000 years ago
- Genesis Marks 10th Anniversary With Magma GT Concept Aimed at High-Performance Flagships
- Tehran defends ship seizure as a legal action, but tensions continue in the Gulf
- The most effective method to Boost Eco-friendliness in Your Volvo XC40
- The Leonid meteor shower is peaking early this week. Here’s what to know
- The most effective method to Shield Your Gold Ventures: Procedures and Precautionary measures
- Special night Objections in Europe
- Tech for Learning: Online Courses and Instructive Apparatuses
